raloxifene hydrochloride has been researched along with Schizophrenia in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.94) | 29.6817 |
| 2010's | 28 (82.35) | 24.3611 |
| 2020's | 5 (14.71) | 2.80 |
| Authors | Studies |
|---|---|
| Edemann-Callesen, H; Felgel-Farnholz, V; Garthe, A; Hadar, R; Hlusicka, EB; Winter, C | 1 |
| Kong, L; Li, L; Li, Z; Liu, L; Tang, Y; Wang, Y; Wang, Z | 1 |
| Brand, BA; de Boer, JN; Grootens, KP; Luykx, JJ; Marcelis, MC; Sommer, IE | 1 |
| Brand, BA; Hamers, IMH; Sommer, IE; Willemse, EJM | 1 |
| Du, X; Hill, RA; Hudson, M; Jones, NC; Nakamura, JP; Schroeder, A; Sundram, S | 1 |
| Cobo, J; Creus, M; Cuadras, D; Franco, J; García-Parés, G; Huerta-Ramos, E; Labad, J; Marcó-García, S; Miquel, E; Núñez, C; Reyes, JC; Usall, J | 1 |
| Burshtein, S; Davis, JM; Grecu, IG; Hagin, M; Levi, L; Matei, VP; Micluția, I; Noy, A; Păcală, B; Podea, D; Tiugan, A; Weiser, M; Zamora, D | 1 |
| Dong, X; Li, X; Wang, Q; Wang, Y | 1 |
| Cai, DB; Grigg, J; Kulkarni, J; Li, XH; Ng, CH; Ning, YP; Ungvari, GS; Wang, XP; Xiang, YT; Yang, XH; Zheng, W; Zhu, XM | 1 |
| Gogos, A; Sbisa, A; van den Buuse, M | 1 |
| González-Rodríguez, A; Seeman, MV | 1 |
| Barbero, JD; Bioque, M; Cobo, J; García-Rizo, C; González-Rodríguez, A; Huerta-Ramos, E; Labad, J; Monreal, JA; Soria, V; Tost, M; Usall, J | 1 |
| Huerta-Ramos, E; Núñez, C; Ramos, B; Usall, J; Vila, È | 1 |
| Gavrilidis, E; Gurvich, C; Hudaib, A; Kulkarni, J; Thomas, N; Worsley, R | 1 |
| Dhandapani, A; Narayanaswamy, JC; Venkatasubramanian, G | 1 |
| Cobo, J; Huerta-Ramos, E; Iniesta, R; Miquel, E; Ochoa, S; Roca, M; Serrano-Blanco, A; Teba, F; Usall, J | 1 |
| Akhondzadeh, S; Fatehi, F; Hashempoor, S; Kashani, L; Khodaei-Ardakani, MR; Kianimehr, G; Nazari, A; Rezaei, F | 1 |
| Huerta-Ramos, E; Miquel, E; Ochoa, S; Roca, M; Usall, J | 1 |
| Catts, SV; Kindler, J; Lenroot, R; Skilleter, AJ; Weickert, CS; Weickert, TW | 1 |
| Gogos, A; van den Buuse, M | 1 |
| Balzan, R; Carr, VJ; Catts, SV; Curtis, J; Galletly, C; Kulkarni, J; Lenroot, R; Liu, D; O'Donnell, M; Pellen, D; Schofield, PR; Short, B; Vercammen, A; Weickert, CS; Weickert, TW; Weinberg, D; Wells, R | 1 |
| Akhondzadeh, S; Khodaie-Ardakani, MR; Khosravi, M; Mohsenian, A; Nejati, S; Tabrizi, M; Zarinfard, R | 1 |
| Goyal, A; Tharoor, H | 1 |
| Cobo, J; Creus, M; Cuadras, D; Franco, J; Huerta-Ramos, E; Labad, J; Miquel, E; Núñez, C; Parés, GG; Reyes, JC; Roca, M; Usall, J | 1 |
| Gur, RE; Ji, E; Kindler, J; Lenroot, R; Skilleter, AJ; Vercammen, A; Weickert, CS; Weickert, TW; White, C | 1 |
| Khan, MM | 1 |
| Berk, M; Davis, SR; Gavrilidis, E; Gilbert, H; Grigg, J; Gurvich, C; Gwini, SM; Kulkarni, J; Warren, A; Worsley, R | 1 |
| Cobo, J; Creus, M; Garcia-Pares, G; Huerta-Ramos, E; Labad, J; Martorell, L; Miquel, E; Núñez, C; Ortega, L; Rubio-Abadal, E; Usall, J; Vilella, E | 1 |
| Grigg, J; Kulkarni, J; Worsley, R | 1 |
| Kindler, J; Lenroot, R; Schofield, PR; Weickert, CS; Weickert, TW | 1 |
| Berk, M; Davis, SR; de Castella, A; Dodd, S; Fitzgerald, PB; Gavrilidis, E; Gilbert, H; Gurvich, C; Kulkarni, J; Lee, SJ | 1 |
| Araya, S; Cobo, J; Huerta-Ramos, E; Iniesta, R; Ochoa, S; Roca, M; Serrano-Blanco, A; Teba, F; Usall, J | 1 |
| Jayaram, N; Rao, NP; Raveendranathan, D; Shivakumar, V; Venkatasubramanian, G | 1 |
| de Castella, A; Gavrilidis, E; Gilbert, H; Gurvich, C; Kulkarni, J; Marston, N; Mehmedbegovic, F; Mu, L | 1 |
7 review(s) available for raloxifene hydrochloride and Schizophrenia
| Article | Year |
|---|---|
Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Estradiol; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Schizophrenia | 2023 |
Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Estrogens; Female; Humans; Hyperprolactinemia; Male; Raloxifene Hydrochloride; Schizophrenia | 2023 |
Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Schizophrenia | 2018 |
Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Middle Aged; Outcome Assessment, Health Care; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Schizophrenia; Selective Estrogen Receptor Modulators | 2018 |
Pharmacotherapy for schizophrenia in postmenopausal women.
Topics: Antipsychotic Agents; Female; Humans; Phytoestrogens; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Schizophrenia; Venous Thromboembolism | 2018 |
Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis.
Topics: Affective Disorders, Psychotic; Bipolar Disorder; Cognition Disorders; Cognitive Dysfunction; Depressive Disorder, Major; Female; Gonadal Steroid Hormones; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Mifepristone; Mood Disorders; Pituitary-Adrenal System; Pregnenolone; Raloxifene Hydrochloride; Schizophrenia | 2018 |
Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.
Topics: Animals; Antipsychotic Agents; Humans; Osteoporosis; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Treatment Outcome | 2016 |
16 trial(s) available for raloxifene hydrochloride and Schizophrenia
| Article | Year |
|---|---|
The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Infant, Newborn; Male; Postmenopause; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Treatment Outcome | 2023 |
Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial.
Topics: Aged; Antipsychotic Agents; Attention; Cognitive Dysfunction; Double-Blind Method; Drug Therapy, Combination; Executive Function; Female; Humans; Memory Disorders; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Treatment Outcome | 2020 |
Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
Topics: Aged; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Psychotic Disorders; Raloxifene Hydrochloride; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2017 |
Specificity proteins 1 and 4 in peripheral blood mononuclear cells in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Estrogen Antagonists; Female; Humans; Leukocytes, Mononuclear; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Raloxifene Hydrochloride; Schizophrenia; Sp1 Transcription Factor; Sp4 Transcription Factor | 2019 |
Raloxifene as a treatment for cognition in women with schizophrenia: the influence of menopause status.
Topics: Adult; Cognition; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Humans; Menopause; Middle Aged; Postmenopause; Premenopause; Psychiatric Status Rating Scales; Raloxifene Hydrochloride; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Selective Estrogen Receptor Modulators; Treatment Outcome | 2019 |
Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
Topics: Antipsychotic Agents; Attention; Double-Blind Method; Executive Function; Female; Humans; Memory; Middle Aged; Neuropsychological Tests; Postmenopause; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Socioeconomic Factors; Time Factors; Treatment Outcome | 2014 |
Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.
Topics: Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Raloxifene Hydrochloride; Risperidone; Schizophrenia; Selective Estrogen Receptor Modulators; Treatment Outcome | 2014 |
Selective Estrogen Receptor Modulation Increases Hippocampal Activity during Probabilistic Association Learning in Schizophrenia.
Topics: Association Learning; Cross-Over Studies; Double-Blind Method; Female; Hippocampus; Humans; Image Processing, Computer-Assisted; Learning Disabilities; Magnetic Resonance Imaging; Male; Oxygen; Raloxifene Hydrochloride; Receptors, Estrogen; Schizophrenia; Selective Estrogen Receptor Modulators | 2015 |
Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Australia; Cross-Over Studies; Double-Blind Method; Estrogen Antagonists; Female; Humans; Longitudinal Studies; Male; Memory Disorders; Middle Aged; Neuropsychological Tests; Patient Compliance; Psychiatric Status Rating Scales; Raloxifene Hydrochloride; Schizophrenia; Sex Characteristics; Statistics, Nonparametric; Treatment Outcome; Young Adult | 2015 |
A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
Topics: Adult; Antipsychotic Agents; Depression; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Psychiatric Status Rating Scales; Raloxifene Hydrochloride; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2015 |
Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.
Topics: Aged; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle Aged; Outcome Assessment, Health Care; Placebos; Postmenopause; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators | 2016 |
Adjunctive selective estrogen receptor modulator increases neural activity in the hippocampus and inferior frontal gyrus during emotional face recognition in schizophrenia.
Topics: Adult; Brain Mapping; Cross-Over Studies; Double-Blind Method; Emotions; Face; Female; Frontal Lobe; Hippocampus; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Nerve Net; Raloxifene Hydrochloride; Recognition, Psychology; Schizophrenia; Selective Estrogen Receptor Modulators | 2016 |
Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
Topics: Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Middle Aged; Psychiatric Status Rating Scales; Psychotic Disorders; Raloxifene Hydrochloride; Schizophrenia; Schizophrenic Psychology | 2016 |
Raloxifene increases prefrontal activity during emotional inhibition in schizophrenia based on estrogen receptor genotype.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Emotions; Estrogen Receptor alpha; Female; Genetic Variation; Genotype; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Middle Aged; Prefrontal Cortex; Raloxifene Hydrochloride; Schizophrenia; Schizophrenic Psychology; Selective Estrogen Receptor Modulators; Young Adult | 2016 |
Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle Aged; Pilot Projects; Placebos; Postmenopause; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Treatment Outcome | 2010 |
Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
Topics: Aged; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle Aged; Placebos; Postmenopause; Psychiatric Status Rating Scales; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Treatment Outcome | 2011 |
11 other study(ies) available for raloxifene hydrochloride and Schizophrenia
| Article | Year |
|---|---|
Adolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia.
Topics: Animals; Behavior, Animal; Cognition; Disease Models, Animal; Female; Humans; Male; Poly I-C; Prenatal Exposure Delayed Effects; Raloxifene Hydrochloride; Rodentia; Schizophrenia | 2023 |
Raloxifene recovers effects of prenatal immune activation on cognitive task-induced gamma power.
Topics: Animals; Behavior, Animal; Biological Clocks; Cognition; Disease Models, Animal; Female; Gamma Rhythm; Immune System; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Psychomotor Performance; Raloxifene Hydrochloride; Schizophrenia | 2019 |
The effect of estrogenic compounds on psychosis-like behaviour in female rats.
Topics: Animals; Apomorphine; Dopamine Agonists; Estradiol; Estrogens; Female; Ovariectomy; Psychotic Disorders; Raloxifene Hydrochloride; Rats; Rats, Long-Evans; Receptors, Dopamine; Schizophrenia; Selective Estrogen Receptor Modulators; Tamoxifen | 2018 |
Adjuvant raloxifene treatment for negative symptoms of schizophrenia.
Topics: Antipsychotic Agents; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2013 |
The effect of raloxifene on symptoms and cognitive functioning in a postmenopausal schizophrenia patient: a case report.
Topics: Antipsychotic Agents; Cognition; Cognition Disorders; Drug Therapy, Combination; Female; Humans; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Treatment Outcome | 2015 |
Comparing the effects of 17β-oestradiol and the selective oestrogen receptor modulators, raloxifene and tamoxifen, on prepulse inhibition in female rats.
Topics: Acoustic Stimulation; Animals; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Estradiol; Estrogens; Female; Ovariectomy; Prepulse Inhibition; Raloxifene Hydrochloride; Random Allocation; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Reflex, Startle; Schizophrenia; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Treatment Outcome | 2015 |
Pharmacogenetic study of the effects of raloxifene on negative symptoms of postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial.
Topics: Age of Onset; Aged; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Estrogen Receptor alpha; Female; Genotype; Glucuronosyltransferase; Humans; Middle Aged; Pharmacogenetics; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Postmenopause; Raloxifene Hydrochloride; Schizophrenia; Schizophrenic Psychology; Selective Estrogen Receptor Modulators | 2016 |
Raloxifene for schizophrenia and symptoms of hyperprolactinaemia?
Topics: Antipsychotic Agents; Humans; Hyperprolactinemia; Prolactin; Raloxifene Hydrochloride; Schizophrenia | 2017 |
Beneficial effects of add-on raloxifene in schizophrenia.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators | 2012 |
Hormone modulation: a novel therapeutic approach for women with severe mental illness.
Topics: Administration, Cutaneous; Adult; Antimanic Agents; Antipsychotic Agents; Clinical Trials as Topic; Cognition Disorders; Drug Therapy, Combination; Estradiol; Female; Humans; Middle Aged; Psychotic Disorders; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |